U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H28F7NO2
Molecular Weight 555.5269
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERLOPITANT

SMILES

[H][C@@]12CN(C[C@@]1([H])[C@@H]([C@H](CC2)O[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=CC=C(F)C=C4)C5=CC(=O)CC5

InChI

InChIKey=FLNYCRJBCNNHRH-OIYLJQICSA-N
InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1

HIDE SMILES / InChI

Molecular Formula C29H28F7NO2
Molecular Weight 555.5269
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Serlopitant, Originally developed by Merck, is a once-daily oral NK1 receptor antagonist being developed for the treatment of pruritus, or itch, associated with various conditions such as prurigo nodularis, psoriasis and chronic pruritus of unknown origin. It is highly selective for the human NK1 receptor and in both animal and human testing it has been well tolerated. In 2012, Merck licensed serlopitant to Menlo to develop it in indications other than nausea and vomiting. Development of serlopitant for the treatment of overactive bladder, alcohol dependence and pruritus was discontinued at phase II, by Merck & Co. and Japan. Menlo has completed three positive Phase 2 clinical trials with serlopitant showing a statistically significant reduction in pruritus compared to placebo. Serlopitant has been evaluated in over 1,600 patients and has been shown to be well-tolerated, including in patients who have received treatment for up to one year. Serlopitant is an investigational drug that is not currently approved for use in any indication in any country.

Approval Year

PubMed

PubMed

TitleDatePubMed
A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
2010 Aug
Patents

Sample Use Guides

In a randomized, double-blind, placebo-controlled study, 128 patients with chronic, treatment-refractory prurigo nodularis (PN) for more than 6 weeks received serlopitant, 5 mg, or placebo orally once daily for 8 weeks.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:31:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:31:29 GMT 2023
Record UNII
277V92K32B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERLOPITANT
INN   USAN  
USAN   INN  
Official Name English
MK-0594
Code English
Serlopitant [WHO-DD]
Common Name English
SERLOPITANT [USAN]
Common Name English
serlopitant [INN]
Common Name English
VPD-737
Code English
Classification Tree Code System Code
NCI_THESAURUS C267
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL447955
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
WIKIPEDIA
Serlopitant
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
SMS_ID
100000156799
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
EVMPD
SUB130838
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
DRUG BANK
DB12973
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
PUBCHEM
23653789
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
INN
8990
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
FDA UNII
277V92K32B
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
CAS
860642-69-9
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
MESH
C551592
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
NCI_THESAURUS
C81499
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID701006599
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
USAN
TT-73
Created by admin on Fri Dec 15 16:31:29 GMT 2023 , Edited by admin on Fri Dec 15 16:31:29 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY